Business
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Spotlight presentation using Guardant Reveal™ test suggests ctDNA has potential to predict sensitivity to endocrine therapy and long-term outcomes in HR+
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nSpotlight presentation using Guardant Reveal™ test suggests ctDNA has potential to predict sensitivity to endocrine therapy and long-term outcomes in HR+ breast cancer\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting long-term outcomes at the San Antonio Breast Cancer Symposium (SABCS) 2024 in San Antonio, Texas, Dec. 10-13, 2024.\n\n\nGuardant and its research partners will present eight posters, including an SABCS Poster Spotlight featuring the use of the Guardant Reveal test, a tissue-free epigenomic assay, to investigate the dynamics of circulating tumor DNA (ctDNA) during neoadjuvant endocrine therapy in HR+ early breast cancer. Study findings suggest that ctDNA has the potential to provide valuable insights into tumor burden, sensitivity to endocrine therapy, and the emergence of endocrine resistance mutations. The investigators conclude that ctDNA could be a valuable tool in predicting long-term outcomes and in tailoring treatment approaches.\n\n\n“Working together with our research collaborators, we continue to establish the important role of Guardant’s precision oncology portfolio in informing treatment selection and monitoring for recurrence and therapeutic response,” said Craig Eagle, M.D., chief medical officer at Guardant Health. “We look forward to sharing new studies at SABCS that show how Guardant is working with researchers and cancer care teams to improve outcomes for people living with breast cancer.”\n\n\nGuardant Health and collaborator poster presentations at SABCS 2024\n\n\n\n\nWednesday, December 11 | 7:00-8:30 am | Hemisfair Ballroom 1-2\n\n\n\n\n\n\n\n\nAbstract\n\n\n\n\n\n\nTitle\n\n\n\n\n\n\nProduct\n\n\n\n\n\n\n\n\nPS7-05\n\n\n\n\n \n\n\n\n\n\n\nSABCS Poster Spotlight\n\n\n\n\nImpact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)\n\n\n\n\n\n\nGuardantINFORM™\n\n\n\n\n\n\n\n\nWednesda...